Background
Observational studies have reported the association between tea consumption and the risk of lower respiratory tract infections (LRTIs). However, a consensus has yet to be reached, and whether the observed association is driven by confounding factors or reverse causality remains unclear.
Method
A two-sample Mendelian randomization (MR) analysis was conducted to determine whether genetically predicted tea intake is causally associated with the risk of common LRTI subtypes. Genome-wide association study (GWAS) from UK Biobank was used to identify single-nucleotide polymorphisms (SNPs) associated with an extra cup of tea intake each day. The summary statistics for acute bronchitis, acute bronchiolitis, bronchiectasis, pneumonia, and influenza and pneumonia were derived from the FinnGen project.
Results
We found that genetically predicted an extra daily cup of tea intake was causally associated with the decreased risk of bronchiectasis [odds ratio (OR) = 0.61, 95% confidence interval (CI) = 0.47–0.78,
P
< 0.001], pneumonia (OR = 0.90, 95% CI = 0.85–0.96,
P
= 0.002), influenza and pneumonia (OR = 0.91, 95% CI = 0.85–0.97,
P
= 0.002), but not with acute bronchitis (OR = 0.91, 95% CI = 0.82–1.01,
P
= 0.067) and acute bronchiolitis (OR = 0.79, 95% CI = 0.60–1.05,
P
= 0.100). Sensitivity analyses showed that no heterogeneity and pleiotropy could bias the results.
Conclusions
Our findings provided new evidence that genetically predicted an extra daily cup of tea intake may causally associated with a decreased risk of bronchiectasis, pneumonia, and influenza and pneumonia.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00394-022-02994-w.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.